Lantheus Holdings Inc
LNTH
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
177.1% upsideUndervalued by 177.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.15 Billion |
|---|---|
| Enterprise Value | $6.65 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $3.46 |
| Beta | -0.04 |
| Outstanding Shares | 64,736,000 |
Return
| Return on Equity | 23.02% |
|---|---|
| Return on Assets | 11.89% |
| Return on Invested Capital | 15.39% |
Valuation & Multiples
| P/E Ratio | 26.08 |
|---|---|
| PEG | 41.84 |
| Price to Sales | 4.78 |
| Price to Book Ratio | 6.11 |
| Enterprise Value to Revenue | 4.3 |
| Enterprise Value to EBIT | 21.47 |
| Enterprise Value to Net Income | 23 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6927▲ 7.33% |
|---|---|
| Total Calls | 339,100▲ 22.82% |
| Total Puts | 234,882▲ 37.36% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 107.68%▲ 4.51% |
|---|---|
| Total Invested | $5.51B▲ 19.34% |
| Investors Holding | 414▲ 13.00% |
ESG Score
No data
About Lantheus Holdings Inc
CEO: Mary Heino Relevant Senate Committees
This committee controls taxation, trade, and entitlement spending, including Medicare pricing, all of which directly and significantly impact the profitability, revenue, and corporate valuations of a healthcare product manufacturer like Lantheus Holdings.
This committee directly regulates the FDA, which is responsible for approving medical products and radiopharmaceuticals like those manufactured by Lantheus Holdings, significantly impacting its core business.
Lantheus Holdings deals with radiopharmaceuticals, making it subject to direct regulation by the Nuclear Regulatory Commission (NRC) and potentially EPA oversight, both under this committee's jurisdiction.